Harvoni (ledipasvir/sofosbuvir)
contains a HCV NS5A inhibitor
(ledipasvir) and a nucleotide
inhibitor of HCV NS5B
RNA‑dependent RNA polymerase
(sofosbuvir). Harvoni is indicated
for the treatment of chronic
hepatitis C (CHC) genotype 1
infection in adults. Harvoni should
not be administered concurrently
with other medicinal products
containing any of the same active
components. Harvoni is available
as a fixed dose combination tablet
containing 90 mg of ledipasvir and
400 mg of sofosbuvir. Harvoni is
available as a bottle of 28 tablets.The above article was sent to subscribers in Pharmacy Daily's issue from 06 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 06 Jul 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.